Dopamine agonists for preventing future miscarriage in women with idiopathic hyperprolactinemia and recurrent miscarriage history
Information
- DOI:
- https://doi.org/10.1002/14651858.CD008883.pub2Copy DOI
- Database:
-
- Cochrane Database of Systematic Reviews
- Version published:
-
- 25 July 2016see what's new
- Type:
-
- Intervention
- Stage:
-
- Review
- Cochrane Editorial Group:
-
Cochrane Pregnancy and Childbirth Group
- Copyright:
-
- Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Article metrics
Altmetric:
Cited by:
Authors
Contributions of authors
Hengxi Chen was responsible for developing the protocol, searching for trials, assessing the quality of trials, extracting data, analyzing data and developing the review.
Jing Fu was responsible for searching for trials, assessing the quality of trials, and extracting data.
Wei Huang was responsible for amending the review.
Sources of support
Internal sources
-
West China Second University Hospital, China.
External sources
-
No sources of support supplied
Declarations of interest
Hengxi Chen ‐ none known.
Jing Fu ‐ none known.
Wei Huang ‐ none known.
Acknowledgements
The authors wish to thank the Managing Editor and the Information Specialist of the Cochrane Pregnancy and Childbirth Group.
This project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to Cochrane Pregnancy and Childbirth. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.
Version history
| Published | Title | Stage | Authors | Version |
| 2016 Jul 25 | Dopamine agonists for preventing future miscarriage in women with idiopathic hyperprolactinemia and recurrent miscarriage history | Review | Hengxi Chen, Jing Fu, Wei Huang | |
| 2010 Dec 08 | Dopamine agonists for preventing future miscarriage in women with idiopathic hyperprolactinemia and recurrent miscarriage history | Protocol | Hengxi Chen, Hu Lina | |
Differences between protocol and review
There are some differences between our published protocol (Chen 2010) and the full version of the review.
Background ‐ we have updated the background.
Methods/types of intervention ‐ we expanded this to include intervention versus no treatment.
Methods/types of outcomes/secondary outcomes ‐ we have edited some secondary outcomes:
'Safety: teratogenicity, developmental disabilities of fetus, et al.' has been replaced by two secondary outcomes ‐
5. Rates of adverse maternal effects: nausea, vomiting, headache, vertigo, fatigue, hypotension, arrhythmia, and psychotic symptoms
6. Rates of adverse fetal outcomes: birth defects, low birthweight, and developmental disabilities
Methods/search methods ‐ this section has been updated to reflect the current standard search methods of Cochrane Pregnancy and Childbirth.
Methods/data collection and analysis ‐ we have used the GRADE approach to assess the quality of the body of evidence.
Methods/sensitivity analysis ‐ we have added that, in future updates, we will carry out sensitivity analysis to investigate the effect of the randomization unit (if relevant).
Keywords
MeSH
Medical Subject Headings (MeSH) Keywords
Medical Subject Headings Check Words
Female; Humans; Pregnancy;
PICOs
'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
Comparison 1 Dopamine agonists alone versus no treatment, Outcome 1 Miscarriages.
Comparison 1 Dopamine agonists alone versus no treatment, Outcome 2 Live births.
Comparison 1 Dopamine agonists alone versus no treatment, Outcome 3 Conception.
| Bromocriptine treatment versus no treatment for preventing future miscarriage in women with idiopathic hyperprolactinemia and recurrent miscarriage history | ||||||
| Patient or population: women with idiopathic hyperprolactinemia and recurrent miscarriage history Comparison: no treatment | ||||||
| Outcomes | Anticipated absolute effects* (95% CI) | Relative effect | No of participants | Quality of the evidence | Comments | |
| Risk with placebo/no treatment | Risk with Dopamine agonists alone | |||||
| Miscarriages | Study population | RR 0.28 | 46 | ⊕⊕⊝⊝ | ||
| 455 per 1000 | 127 per 1000 | |||||
| Moderate | ||||||
| 455 per 1000 | 127 per 1000 | |||||
| Live births | Study population | RR 1.50 | 46 | ⊕⊝⊝⊝ | ||
| 500 per 1000 | 750 per 1000 | |||||
| Moderate | ||||||
| 500 per 1000 | 750 per 1000 | |||||
| Conception | Study population | RR 0.92 | 46 | ⊕⊝⊝⊝ | ||
| 955 per 1000 | 878 per 1000 | |||||
| Moderate | ||||||
| 955 per 1000 | 878 per 1000 | |||||
| Proportion reduction in serum prolactin levels | Study population | Not estimable | 0 | See comment | No data in included study | |
| See comment | See comment | |||||
| Moderate | ||||||
| Serum prolactin normalization | Study population | Not estimable | 0 | See comment | No data in included study | |
| See comment | See comment | |||||
| Moderate | ||||||
| Adverse maternal effects | Study population | Not estimable | 0 | See comment | No data in included study | |
| See comment | See comment | |||||
| Moderate | ||||||
| Adverse fetal outcomes | Study population | Not estimable | 0 | See comment | No data in included study | |
| See comment | See comment | |||||
| Moderate | ||||||
| *The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). | ||||||
| GRADE Working Group grades of evidence High quality: we are very confident that the true effect lies close to that of the estimate of the effect Moderate quality: we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low quality: our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect Very low quality: we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect | ||||||
| 1 One trial with design limitations, including no description of allocation concealment, lack of blinding and possible outcome reporting bias (‐1). | ||||||
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
| 1 Miscarriages Show forest plot | 1 | 46 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.28 [0.09, 0.87] |
| 2 Live births Show forest plot | 1 | 46 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.5 [0.93, 2.42] |
| 3 Conception Show forest plot | 1 | 46 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.92 [0.77, 1.09] |
